EUVIMEDEUVIMED entdecken
Crossref

Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study

Pamela L. Lutsey, Devon M. Sauerer, Erin D. Michos, Elizabeth Selvin, Casey M. Rebholz, Rebecca F. Gottesman, Alvaro Alonso, Kunihiro Matsushita, Sanaz Sedaghat

Journal of Alzheimer’s Disease · 21.11.2026

DOI: 10.1177/13872877261507035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 21.11.2026. Verfasst von Pamela L. Lutsey und 8 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Gefördert von: American Heart Association, National Institute of Neurological Disorders and Stroke, National Institute on Aging.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elevated concentrations of fibroblast growth factor 23 (FGF23), a hormone involved in bone mineral and vitamin D metabolism, may be associated with risk of stroke and dementia through inflammation, endothelial dysfunction, vessel calcification and stiffness, and axonal degeneration.

Objective

We tested the hypothesis that elevated FGF23 is associated with increased risk of dementia and stroke.

Methods

FGF23 was measured in serum samples collected in 1990–1992 from 12,391 participants of the Atherosclerosis Risk in Communities study. Participants were followed through 2019 for incident stroke and dementia. Cox regression was used to examine the associations of FGF23 (in quintiles) with risk of stroke and dementia, with adjustment for demographics, cardiovascular and dementia risk factors, and kidney function.

Results

Participants (mean 56.9 years; 57% female) were followed a median of 24 years; 1183 developed stroke and 2402 developed dementia. Participants in the highest versus lowest quintile of serum FGF23 were at elevated risk of stroke [HR (95% CI): 1.27 (1.06–1.51)] and dementia [HR: 1.21 (1.06–1.38)] independent of baseline demographics. Associations attenuated with additional adjustment for traditional cardiovascular risk factors [HR stroke : 1.20 (1.00–1.45); HR dementia : 1.17 (1.03–1.35)], and became even weaker after accounting for eGFR [HR stroke : 1.13 (0.94–1.37); HR dementia : 1.14 (1.00–1.31)]. The associations of FGF23 with incident stroke and dementia were not modified by categories of age, sex, race, or eGFR.

Conclusions

Higher FGF23 was associated with modestly greater risk of stroke and dementia in this population-based sample, though the association was largely attenuated after adjustment for traditional cardiovascular risk factors and kidney function.

Förderung

  • American Heart Association
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Lutsey, P. L., Sauerer, D. M., Michos, E. D., Selvin, E., Rebholz, C. M., Gottesman, R. F., Alonso, A., Matsushita, K., & Sedaghat, S. (2026). Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261507035

Vancouver

Lutsey PL, Sauerer DM, Michos ED, Selvin E, Rebholz CM, Gottesman RF, et al. Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261507035

BibTeX
@article{Lutsey2026,
  author = {Lutsey, Pamela L. and Sauerer, Devon M. and Michos, Erin D. and Selvin, Elizabeth and Rebholz, Casey M. and Gottesman, Rebecca F. and Alonso, Alvaro and Matsushita, Kunihiro and Sedaghat, Sanaz},
  title = {Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study},
  journal = {Journal of Alzheimer’s Disease},
  year = {2026},
  doi = {10.1177/13872877261507035}
}
Kostenlos starten →